CAR T-Cell Therapy

Evaluating the Potential for CAR T Cells as Treatment of Solid Tumors

June 15, 2020

Prasad S. Adusumilli, MD, FACS, discusses the potential role of chimeric antigen receptor T-cell therapy as treatment of solid tumors now that they have demonstrated safety and efficacy in some Hematologic Malignancies.

CAR T Cells May Be Safely Administered in Outpatient Setting for Patients With B-Cell Lymphomas

June 10, 2020

In an interview with Targeted Oncology, David G. Maloney, MD, PhD, discussed findings from administration of chimeric antigen receptor T-cell therapy in the outpatient setting for patients with B-cell lymphomas.

Optimized Tandem CAR T-Cell Therapy Targeted CD19/CD20 Appears Feasible in B-NHL

June 02, 2020

Although many of the patients in the study had heavy tumor burden, were in poor physical condition, or had highly aggressive characteristics, they were still able to achieve a satisfactory overall response rate and complete response rate with the tandem CD19/CD20 CAR-engineered T-cell therapy.

Novel CAR-T Cell Therapy Combination Shows Preliminary Activity in R/R B-cell Lymphoma

May 30, 2020

A pair of off-the-shelf CAR T-cell agents have shown promise for the treatment of relapsed/refractory large B-cell or follicular lymphoma, according to the phase 1 ALPHA study.

Integrating EMR Into the Clinical Management of CAR T-Cell Therapy Improves Patient Care

May 14, 2020

In an interview with Targeted Oncology, Andrea Price, APN, discussed the importance of integrating the electronic medical record team into the clinical care team for the treatment of patients with cancer receiving CAR T-cell therapy.

FDA Halts Review of BLA for Ide-cel in R/R Multiple Myeloma Pending Additional Data

May 13, 2020

The review of the Biologics License Application for idecabtagene vicleucel has been put on hold. The FDA issued a Refusal to File letter due to the need for additional data from the developer of the drug.

Protocol Management, Off-the-Shelf Therapies Help Bring CAR T Into More Settings

May 12, 2020

Relevant professional meetings and oncology publications exploded with research and news about chimeric antigen receptor T cells, and this cellular therapy strategy is now being explored across hematologic and solid malignancies.

Higher CAR T-Cell Dosage Improves Efficacy Without Toxicity in Relapsed or Refractory CLL

May 10, 2020

Patients with relapsed or refractory chronic lymphocytic leukemia who received a higher dose of CAR T cells, achieved complete responses, regardless of cell dose, which was highly correlated with long-term survival.

FDA Extends Target Action Date for Liso-cel in R/R Large B-cell Lymphoma

May 06, 2020

The FDA extended the Prescription Drug User Fee Act target action date for liso-cel due to the submission of additional information by the drug developer, which will require additional time to review.

Exploring the Current Role of CAR T Cells in Acute Lymphoblastic Leukemia

May 01, 2020

Jae Park, MD, discusses his key takeaways from chimeric antigen receptor T cells in the treatment landscape of patients with acute lymphoblastic leukemia.